Sphere Fluidics expands to increase supply of surfactant for droplet microfluidics
Investment in resources to meet demand for large-scale supply of patented biocompatible surfactant.
Sphere Fluidics has announced an investment in the production and supply of its proprietary biocompatible surfactant, Pico-Surf, for reliable and highly stable droplet generation and processing. Sphere Fluidics will expand operations to meet demand for large-scale commercial supply of its high-performing surfactant for use in a wide range of microfluidic application workflows.
Pico-Surf is a high-quality and animal-origin-free biocompatible surfactant optimized to support the formation of aqueous solution-in-oil picodroplets. Sphere Fluidics aims to increase production of Pico-Surf by three-fold in 2020, while maintaining its industry-leading standards, through significant investment of resources in manufacture and quality control processes, and workforce. As part of the company's range of specialist chemicals, Pico-Surf is designed to work effectively and flexibly across a broad range of microfluidic systems, including the Sphere Fluidics' proprietary single cell analysis platforms and applications, such as molecular biology assays, cell secretion assays and cell growth studies.
The unique and patented molecular structure of Pico-Surf stabilizes droplets, and retains and protects their cellular and molecular contents over a wide range of temperatures and biological conditions, helping to ensure high cell viability for improved assay performance. Droplets generated using Pico-Surf show low end point interfacial tension and critical micelle concentration in comparison to other commercially available surfactants. The purity and quality of the surfactant also enables a more efficient droplet sorting process at low voltage. The ready-to-use surfactant is available in large batches or made-to-order with ensured lot-to-lot consistency.
Dr Marian Rehak, Vice President of Research and Development, Sphere Fluidics, said: “We are enthused by the increased demand for Pico-Surf, and eager to mobilize its production to meet demand. While doing so, we will ensure its very high-quality control standards are maintained, meaning researchers can continue to rely on Pico-Surf to create droplets that are stable and reproducible.”
Rob Treanor, Director of Operations, Sphere Fluidics, commented: “Sphere Fluidics’ world-leading expertise in picodroplet technology has enabled the development of an ever-growing range of high-performing patented consumables, vital for the successful use of microfluidic systems. All our consumable products have been designed to be platform-agnostic, so they work effectively with a number of microfluidic systems.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...